India鈥檚 First Indigenous Biomedical Waste Plant Opens
13 Feb 2025
1 Min Read
CW Team
Union Minister Dr. Jitendra Singh inaugurated India鈥檚 first indigenous Automated Biomedical Waste Treatment Plant, 鈥楽?janam,鈥� at AIIMS New Delhi. Developed by CSIR-NIIST, the plant offers a sustainable alternative to incineration by disinfecting pathogenic waste without harmful emissions.
With an initial capacity to handle 400 kg of biomedical waste per day, 鈥楽?janam鈥� neutralizes odors and treats infectious materials like blood, urine, and laboratory disposables. The system, currently undergoing validation and regulatory approval, could revolutionize biomedical waste management in India.
India generates 743 tonnes of biomedical waste daily, according to a 2023 CPCB report. Traditional incineration poses health and environmental risks, making this new technology a crucial step in waste management. Third-party validation confirms its antimicrobial effectiveness, with studies suggesting treated material is even safer than organic fertilizers like vermicompost.
During the event, Singh also highlighted India鈥檚 recent scientific advancements, including indigenous DNA and HPV vaccines, the antibiotic Nafithromycin, and gene therapy trials. He outlined key government initiatives, such as Rs 500 billion for the Anusandhan National Research Foundation and Rs 200 billion for Bharat Small Modular Reactors.
With a growing focus on research and sustainability, 鈥楽?janam鈥� marks a significant milestone in India鈥檚 biomedical waste management efforts.
Union Minister Dr. Jitendra Singh inaugurated India鈥檚 first indigenous Automated Biomedical Waste Treatment Plant, 鈥楽?janam,鈥� at AIIMS New Delhi. Developed by CSIR-NIIST, the plant offers a sustainable alternative to incineration by disinfecting pathogenic waste without harmful emissions.
With an initial capacity to handle 400 kg of biomedical waste per day, 鈥楽?janam鈥� neutralizes odors and treats infectious materials like blood, urine, and laboratory disposables. The system, currently undergoing validation and regulatory approval, could revolutionize biomedical waste management in India.
India generates 743 tonnes of biomedical waste daily, according to a 2023 CPCB report. Traditional incineration poses health and environmental risks, making this new technology a crucial step in waste management. Third-party validation confirms its antimicrobial effectiveness, with studies suggesting treated material is even safer than organic fertilizers like vermicompost.
During the event, Singh also highlighted India鈥檚 recent scientific advancements, including indigenous DNA and HPV vaccines, the antibiotic Nafithromycin, and gene therapy trials. He outlined key government initiatives, such as Rs 500 billion for the Anusandhan National Research Foundation and Rs 200 billion for Bharat Small Modular Reactors.
With a growing focus on research and sustainability, 鈥楽?janam鈥� marks a significant milestone in India鈥檚 biomedical waste management efforts.
Next Story
Reliance, Diehl Advance Pact for Precision-Guided Munitions
Diehl Defence CEO Helmut Rauch and Reliance Group鈥檚 Founder Chairman Anil D. Ambani have held discussions to advance their ongoing strategic partnership focused on Guided and Terminally Guided Munitions (TGM), under a cooperation agreement originally signed in 2019.This collaboration underscores Diehl Defence鈥檚 long-term commitment to the Indian market and its support for the Indian Government鈥檚 Make in India initiative. The partnership鈥檚 current emphasis is on the urgent supply of the Vulcano 155mm Precision Guided Munition system to the Indian Armed Forces.Simultaneously, the 鈥淰ulc..
Next Story
Modis Navnirman to Migrate to Main Board, Merge Subsidiary
Modis Navnirman Limited has announced that its Board of Directors has approved a key strategic initiative involving migration from the BSE SME platform to the Main Board of both BSE and NSE, alongside a merger with its wholly owned subsidiary, Shree Modis Navnirman Private Limited.The move to the main boards marks a major milestone in the company鈥檚 growth trajectory, reflecting its consistent financial performance, robust corporate governance, and long-term commitment to value creation. This transition will grant the company access to a broader investor base, improve market participation, en..
Next Story
Global Capital Flows Remain Subdued, EMEA Leads in Q1 2025
The Bharat InvITs Association鈥檚 industry update for Q1 2025 shows subdued global capital flows, with investment volumes remaining at the lower end of the five-year range despite a late 2024 recovery. According to data from Colliers and MSCI Real Capital Analytics, activity in North America declined slightly, while EMEA maintained steady levels and emerged as the top region for investment in standing assets.The EMEA region now hosts seven of the top ten cross-border capital destinations for standing assets, pushing the United States鈥� share of global activity below 15 per cent. Meanwhile, in..
